PHARMAC-NEWER DRUGS

Discussion in 'AIIMS Nov 2013' started by samuel, Aug 21, 2014.

  1. samuel

    samuel New Member

    1. Aliskiren: Renin Inhibitor
    2. Ambrisentan: Endothelin receptor
    antagonist for treatment of
    pulmonary hypertension.
    3. Anidulafungin: Echinocandin
    antifungal for treatment of
    candidemia, abcess, oesophagial
    candidasis.
    4. Armodafinil : CNS stimulant, R-
    enantiomer of Modafinil
    5. Atomoxetine: CNS noradrenaline
    (NA) reuptake inhibitor, first and
    only FDA approved non-stimulant
    drug for treatment of ADHD.
    6. Bosentan: Endothelin-1-
    Antagonist, Cardiac remodeling
    inhibitor. Used for Rx of PPH.
    7. Candoxatrilat: Inhibit Neutral
    Endopeptidase, increases ANP.
    8. Carperitide: Recombinant BNP.
    9. Cinacalcet is an oral calcimimetic
    agent that increases the sensitivity of
    the calcium-sensing receptor to
    activation by extracellular calcium.
    The calcium-sensing receptors on the
    surface of parathyroid gland cells
    also regulate parathyroid hormone
    (PTH) secretion. Increasing the
    sensitivity of these receptors results
    in lowering of PTH which
    subsequently lowers serum calcium
    levels. In addition, significant
    reductions in calcium may lower the
    threshold for seizures. Sensipar is an
    oral calcimimetic medication that
    lowers the levels of parathyroid
    hormone, phosphurous and calcium
    in patients undergoing kidney
    dialysis or in patients with
    parathroid cancer. Cinacalcet
    (Senipar) is indicated for the
    treatment of secondary
    hyperparathyroidism in chronic
    kidney disease patients on dialysis
    and the treatment of elevated
    calcium levels (hypercalcemia) in
    patients with parathyroid carcinoma.
    The recommended starting oral dose
    of Sensipar is 30 mg once daily.
    10. Conivaptan is a non-peptide dual
    arginine vasopressin (AVP) V1A and
    V2 receptor antagonist. It is designed
    to inhibit the effects of AVP, also
    known as antidiuretic hormone
    (ADH), is specifically indicated for
    the treatment of SIADH. . In the
    kidneys, AVP's activity (primarily at
    V2 receptors) inhibits aquaresis, or
    excretion of free water. By exerting
    antagonistic activity at both V1A and
    V2 receptors, the drug is designed to
    inhibit inappropriate/excessive AVP
    secretion, thereby increasing rates
    aquaresis. Increased water secretion
    is correlated with net fluid loss,
    increased urinary output, and
    decreased urinary osmolality. Can
    cause hypokalemia, edema,
    pollakuria(daytime excessive
    urination)
    11. Darunavir: Protease Inhibitor.
    12. Dofetilide: Potassium Channel
    Blocker.
    13. Enoximone: PDE IIIa inhibitor
    (Amrinone/Milrinone)
    14. Eplerenone: Aldosterone
    antagonist.
    15. Etomoxir: pFOX (Fatty acid
    oxidase) inhibitor.
    16. Guanfacine: a selective alpha-2A-
    adrenoceptor agonist of CNS for
    ADHD.
    17. HPV Vaccine (GARDASIL) against
    HPV 6, 11, 16 and 18.
    18. Irinotecan: Topoisomerase 1
    inhibitor, called CPT-11, a
    Camptothecin molecule, anti-
    leukemia agent, also useful in Colon
    carcinoma, producing a metabolite
    SN-38 which produces secretory
    diarrhoea manageable with
    Loperamide or Octreotide, and also
    myelosuppression especially with
    patients with deficient UGT1A1.
    19. Istaroxime: Na+/K+ -ATPase
    inhibitor (E.g. Digoxin), FIRST DRUG
    to target LUSITROPY.
    20. Ixabepilone: Microtubule
    inhibitor for monotherapy for
    metastatic breast cancer after
    treatment failure with other agents.
    21. Lapatinib : Kinase inhibitor used
    in metastatic breast cancer with
    HER2 overexpression.
    22. Lenalidomide is an orally
    available thalidomide analog,
    exerting both anti-angiogenic and
    immunomodulatory/anti-
    inflammatory properties.
    Thrombocytopenia and neutropenia
    were the most frequently observed
    serious adverse events.
    23. Lenalidomide: An IMID –
    Immunomodulatory derivative of
    Thalidomide.
    24. Levosimendan: Calcium
    sensitizer.
    25. Maprotiline: 2nd gen.
    antidepressant, with predominant NA
    reuptake inhibitor, little
    anticholinergic side effects, but may
    produce seizures.
    26. Maraviroc – the first
    chemokine receptor antagonist, Entry
    Inhibitor for drug resistant HIV
    infection. Maraviroc blocks the main
    route of virus entry into uninfected
    cells—chemokine receptor 5 (CCR5).
    27. Mecasermin contains
    recombinant-DNA-engineered human
    insulin-like growth factor-1
    (rhIGF-1). It is designed to replace
    natural IGF-1 in pediatric patients
    who are deficient, promoting
    normalized stature growth. Patients
    with severe primary IGF-1 deficiency
    (Primary IGFD) fail to produce
    adequate levels of IGF-1, due to
    disruption of the growth hormone
    (GH) pathway used to promote IGF-1
    release (possible GH pathway
    disruptions include mutations in the
    GH receptor (GHR), post-GHR
    signaling pathway, and IGF-1 gene
    defects) and is specifically indicated
    for the long-term treatment of
    growth failure in pediatric patients
    with Primary IGFD or with GH gene
    deletion who have developed
    neutralizing antibodies to GH. It is
    not indicated to treat Secondary
    IGFD resulting from GH deficiency,
    malnutrition, hypothyroidism or
    other causes; it is not a substitute for
    GH therapy.
    28. Modafinil: for patients with
    narcolepsy, sleep apnea, and shift
    work sleep disorder.
    29. Natalizumab: recombinant
    humanized IgG4k monoclonal
    antibody produced in murine
    myeloma cells and is indicated for
    the treatment of patients with
    relapsing forms of multiple sclerosis
    to reduce the frequency of clinical
    exacerbations, 300 mg IV infusion
    every four weeks.
    30. Nesiritide: Recombinant BNP.
    31. Omapatrilat: Inhibits both ACE
    and Neutral Endopeptidase.
    32. Pegaptanib: is a selective
    vascular endothelial growth factor
    (VEGF) antagonist, is indicated for
    the treatment of neovascular (wet)
    age-related macular degeneration.
    33. Pemetrexed is a chemotherapy
    drug that interferes with three folic
    acid related enzymes (an antifolate
    antineoplastic agent), is indicated, in
    combination with Cisplatin, for the
    treatment of malignant pleural
    mesothelioma whose disease is
    unresectable or who are otherwise
    not candidates for curative surgery.
    34. Perhexiline: pFOX (Fatty acid
    oxidase) inhibitor.
    35. Raltegravir – is the first
    integrase inhibitor for drug resistant
    HIV infection.
    36. Rifaximin - treatment of
    travelers’ diarrhea caused by
    noninvasive strains of Escherichia
    coli in patients 12 years old and
    older.
    37. Sorafenib is a multikinase
    inhibitor targeting a number of
    serine/threonine and receptor
    tyrosine kinases, is specifically
    indicated for the treatment of
    advanced renal cell carcinoma (RCC).
    38. Tezosentan: Endothelin-1-
    Antagonist, Cardiac remodeling
    inhibitor.
    39. Tipranavir is a non-peptide
    protease inhibitor which selectively
    inhibits virus-specific processing of
    viral Gag and Gag-pol polyproteins,
    preventing formation of functional
    mature virions.
    40. Ularitide: Recombinant
    Urodilantin, a natriuretic peptide
    similar to ANP, BNP.
    41. Zoledronic Acid: First one yearly
    therapy for Osteoporosis, for Pagetâ
    €™s disease and post-menopausal
    osteoporosis.

Share This Page